Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Aug 29, 2012
WellPoint Rallies after Ousting CEO
WellPoint CEO Angela Braley resigned as a result of pressure from shareholders. We still prefer the Health Care SPDR ETF. Aug 20, 2012
Aetna Nabs Coventry
Consolidation continues in the health insurer space, as Aetna acquires Coventry, a company leveraged to Medicaid. Aug 17, 2012
Our Outlook for the Market
President of Equity Research & ETF Analysis, Brian Nelson offers insight into Valuentum's outlook for the market. Aug 16, 2012
Hedge Fund Manager Bets Big on Health Insurers
Hedge fund manager David Einhorn established positions in several large health insurers. We like the move, but prefer the Healthcare Select Sector SPDR (XLV). Jul 31, 2012
Pfizer Reports Decent Second Quarter Results; Plans to Spin Off Animal Health Business
Pfizer posted decent second-quarter results that showed strong cost containment in the face of declining sales of its blockbuster drug Lipitor. The company also announced plans to spin off its animal health business to focus on its core pharma business. We maintain our view that Pfizer is significantly underpriced. Jul 19, 2012
Our Outlook for the Market
President of Equity Research & ETF Analysis, Brian Nelson offers insight into Valuentum's outlook for the market. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
